Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 1.00 |
| ▸ | SCARB1 | Q8WTV0 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rimcazole SCHEMBL29710924 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SCARB1MEN1KMT2AALDH1A1 | |
| Rimcazole SCHEMBL3237432 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SCARB1MEN1KMT2AALDH1A1 | |
| Rimcazole SCHEMBL31395408 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SCARB1MEN1KMT2AALDH1A1 | |
| Rimcazole SCHEMBL6257536 | 0.98 | SIGMAR1 (0.97) | SIGMAR1SCARB1MEN1KMT2AALDH1A1 | |
| Rimcazole SCHEMBL7410252 | 0.98 | SIGMAR1 (0.97) | SIGMAR1SCARB1MEN1KMT2AALDH1A1 | |
| Rimcazole SCHEMBL122161 | 0.98 | SIGMAR1 (0.97) | SIGMAR1SCARB1MEN1KMT2AALDH1A1 | |
| Rimcazole SCHEMBL7411898 | 0.97 | MEN1 (1.00) | SIGMAR1SCARB1MEN1KMT2AALDH1A1 | |
| Rimcazole SCHEMBL7411904 | 0.97 | MEN1 (1.00) | SIGMAR1SCARB1MEN1KMT2AALDH1A1 | |
| Rimcazole SCHEMBL3627653 | 0.97 | MEN1 (1.00) | SIGMAR1SCARB1MEN1KMT2AALDH1A1 | |
| Rimcazole SCHEMBL7414121 | 0.92 | SIGMAR1 (0.85) | SIGMAR1SCARB1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125762-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | UNIV DREXEL (US) | 2026-05-07 | — | — | US | claimed |
| WO-2025031979-A1 | USE OF RIMCAZOLE TO TREAT CANCER | KYREXA LTD (GB) | 2025-02-13 | — | — | WO | claimed |
| US-20240398978-A1 | Compositions and Methods for Treating Dopamine Disorders | METAQOR LLC (US) | 2024-12-05 | — | — | US | claimed |
| US-20240254561-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | THOMAS JEFFERSON UNIVERSITY | 2024-08-01 | — | — | US | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-20210379016-A1 | THERAPEUTICS AND METHODS OF TREATMENT OF ANGIOTENSIN-CONVERTING ENZYME 2 ASSOCIATED CONDITIONS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2021-12-09 | — | — | US | claimed |
| US-20210353771-A1 | Compositions and Methods for Treating Dopamine Disorders | METAQOR LLC | 2021-11-18 | — | — | US | claimed |
| EP-3727361-A1 | TREATMENT OF PAIN AND/OR PAIN RELATED SYMPTOMS ASSOCIATED WITH DYSMENORRHEA | Alyra Biotech Pty Ltd (AU) | 2020-10-28 | — | — | EP | claimed |
| US-20200087730-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | UNIV DREXEL (US) | 2020-03-19 | — | — | US | claimed |
| US-20180256720-A1 | COMPOSITIONS AND METHODS FOR TREATING HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2018-09-13 | — | — | US | claimed |
| WO-2000000599-A2 | COMPOSITION FOR THE INDUCTION OF APOPTOSIS IN TARGET CELLS | UNIVERSITY OF DUNDEE (GB) | 2000-01-06 | — | — | WO | claimed |
| EP-0580776-A1 | USE OF SIGMA RECEPTOR ANTAGONISTS TO ENHANCE THE EFFECTS OF ANTIPSYCHOTIC DRUGS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-02-02 | — | — | EP | claimed |
| US-5180729-A | Phthalimidoalkylpiperidine as narcotic antagonist | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-01-19 | — | — | US | claimed |
| WO-1992018127-A1 | USE OF SIGMA RECEPTOR ANTAGONISTS TO ENHANCE THE EFFECTS OF ANTIPSYCHOTIC DRUGS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-10-29 | — | — | WO | claimed |
| WO-1992014464-A1 | USE OF SIGMA RECEPTOR ANTAGONISTS FOR TREATMENT OF COCAINE ABUSE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-09-03 | — | — | WO | claimed |
| US-4400383-A | 9-(3-(3,5-CIS-DIMETHYLPIPERAZINO/PROPYL)CARBAZOLE | BURROUGHS WELLCOME CO. (US) | 1983-08-23 | — | — | US | claimed |
| US-4379160-A | Carbazole compounds and medicinal use thereof | BURROUGHS WELLCOME CO. (US) | 1983-04-05 | — | — | US | claimed |
| EP-0012208-B1 | 9-(3-(3,5-CIS-DIMETHYLPIPERAZINO)PROPYL)-CARBAZOLE, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | THE WELLCOME FOUNDATION LIMITED (GB) | 1983-01-26 | — | — | EP | claimed |
| EP-0051321-A1 | Cis-dimethylpiperazines for the preparation of N-substituted carbazoles | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-05-12 | — | — | EP | claimed |
| EP-0012208-A2 | 9-(3-(3,5-cis-Dimethylpiperazino)propyl)-carbazole, its preparation and pharmaceutical compositions containing it | THE WELLCOME FOUNDATION LIMITED (GB) | 1980-06-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210379016-A1 | THERAPEUTICS AND METHODS OF TREATMENT OF ANGIOTENSIN-CONVERTING ENZYME 2 ASSOCIATED CONDITIONS | ACE2, ACE, AGTR2 | SIGMAR1 10/4885SCARB1 332/4885MEN1 2219/4885 |
| US-20200087730-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | SIGMAR1, TMEM97, OPRK1 | SIGMAR1 1/4885SCARB1 106/4885MEN1 2395/4885 |
| US-20240254561-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | SIGMAR1, TMEM97, OPRK1 | SIGMAR1 1/4885SCARB1 106/4885MEN1 2395/4885 |
| US-20210353771-A1 | Compositions and Methods for Treating Dopamine Disorders | SLC6A3, SNCA, CLTA | SIGMAR1 182/4885SCARB1 883/4885MEN1 4442/4885 |
| US-20240398978-A1 | Compositions and Methods for Treating Dopamine Disorders | SLC6A3, SNCA, CLTA | SIGMAR1 182/4885SCARB1 883/4885MEN1 4442/4885 |
| US-20260125762-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | IGF2BP3, RBM3, MORF4L1 | SIGMAR1 9/4885SCARB1 1053/4885MEN1 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.